Armistice Capital LLC Sells 61,250 Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX)

Armistice Capital LLC lessened its holdings in shares of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) by 72.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,750 shares of the company’s stock after selling 61,250 shares during the quarter. Armistice Capital LLC owned 3.81% of Salarius Pharmaceuticals worth $54,000 as of its most recent SEC filing.

Salarius Pharmaceuticals Stock Performance

Salarius Pharmaceuticals stock opened at $1.44 on Friday. The firm’s fifty day moving average price is $1.94 and its two-hundred day moving average price is $3.00. The firm has a market capitalization of $856,695.00, a price-to-earnings ratio of -0.07 and a beta of 0.95. Salarius Pharmaceuticals, Inc. has a 1-year low of $1.35 and a 1-year high of $7.60.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings results on Friday, August 9th. The company reported ($2.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($53.60) by $51.23. On average, research analysts forecast that Salarius Pharmaceuticals, Inc. will post -214.4 EPS for the current year.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.